Complete response to twice-a-day interferon-beta with standard interferon-alpha therapy in acute hepatitis C after a needle-stick

Journal of Clinical Gastroenterology

Volumn 28, Issue 1, 1999, Pages 49-51

  Oketani, Makoto ^a   Higashi, Takanori ^a   Yamasaki, Narihiro ^a   Shinmyozu, Koichi ^a   Osame, Mitsuhiro ^a   Arima, Terukatsu ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Acute hepatitis; Hepatitis C virus; Interferon alpha; Interferon beta

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; HEPATITIS C ANTIBODY; LYMPHOBLAST INTERFERON; RECOMBINANT BETA INTERFERON; VIRUS RNA;

ACUTE HEPATITIS; ADULT; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG MEGADOSE; HEPATITIS C; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEEDLESTICK INJURY; NEUROTOXICITY; PARESTHESIA; PHYSICIAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; INTERFERON-ALPHA; INTERFERON-BETA; MALE; NEEDLESTICK INJURIES; TREATMENT OUTCOME;

EID: 0032944896     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-199901000-00013     Document Type: Article

References (16)

1. Vaglia A, Nicolin R, Puro V, et al. Needlestick hepatitis C virus seroconversion in a surgeon. Lancet 1990;336:1315-1316.
2. Kiyosawa K, Sodeyama T, Tanaka E, et al. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med 1991;115:367-369.
3. Viladomiu L, Genesca J, Esteban JI, et al. Interferon-α in acute posttransfusion hepatitis C: a randomized, controlled trial. Hepatology 1992;15:767-769.
4. Lambertico P. Rumi M, Romeo R, et al. A multicenter randomized controlled trial of recombinant interferon-α-2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994;19:19-22.
5. Giuberti T, Marin MG, Ferrari C, et al. Hepatitis C virus viremia following clinical resolution of acute hepatitis C. J Hepatol 1994;20:666-671.
6. Vogel W, Graziadei I, Umlauft F, et al. High-dose interferon-α-2b treatment prevents chronicity in acute hepatitis C. A pilot study. Dig Dis Sci 1996;41:815-855.
7. Lam NP, Neuman AU, Ureth DR, et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-231.
8. Omata M, Yokosuka O, Takano S, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991;338:914-915.
9. Takano S, Satomura Y, Omata M, and Japan Acute Hepatitis Cooperative Study Group. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Gastroenterology 1994;107:805-811.
10. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus genotypes are tha main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995;22:1050-1056.
11. Karino Y, Toyota J, Sugawara M, et al. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am J Gastroenterol 1997;92:61-65.
12. Miyake K, Takikawa H, Yamanaka M. Side effects of interferon therapy in chronic hepatitis C. In: Yamanaka M, Okabe K, Toda G, eds. Interferon Therapy on Chronic Hepatitis C: Progress in Hepatology. Vol. 2. Elsevier Science B.V., Amsterdam, 1996:61-65.
13. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med 1987;147:1577-1580.
14. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of Interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest 1995;96:224-230.
15. Okushin H, Mon K, Kishi F, Yuasa S. Efficacy of the combination therapy usung twice-a-day IFN-β followed by IFNα-2b in treatment for chronic hepatitis C. Kanzou 1997;38:11-18.
16. Borden E, Hogan T, Voelkel J. The comparative antiproliferative activity in vitro on natural interferons α and β for diploid and transformed cells. Cancer Res 1982;42:4948-4953.